Work

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets

Year: 2016

Type: article

Abstract: UNLABELLED: For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. ( CLINICAL TRIAL: NCT02014558; registered at: 〈https://clinicaltrials.gov/ct2/show/NCT02014558〉).

Source: Leukemia Research Reports

DOI: 10.1016/j.lrr.2016.01.002

Authors: Pashtoon M. Kasi, Mark R. Litzow, Mrinal M. Patnaik, Shahrukh K. Hashmi, Naseema Gangat

Institution: Mayo Clinic

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,180